This article presents a brief overview of the etiology of chronic wounds of the lower extremities and their current medical and surgical treatment. Gene therapy as a potential tool for treating therapeutically challenging wounds is described in terms of the vectors employed in gene transfer, as well as thestrategies used to promote wound healing. Results from animal model studies, as well as clinical trials, are presented.
Get full access to this article
View all access options for this article.
References
1.
1. Nelzen O, Bergqvist D, Lindhagen A. Venous and non-venous leg ulcers: clinical history and appearance in a population study. Br J Surg1994;81(2):182-187.
2.
2. Ruckley CV. Socioeconomic impact of chronic venous insufficiency and leg ulcers. Angiology1997;48(1):67-69.
3.
3. Nelzen O, Bergqvist D, Lindhagen A. Leg ulcer etiology—a cross sectional population study. J Vasc Surg1991;14(4):557-564.
4.
4. Burnand KG, Whimster I, Naidoo A, et al. Pericapillary fibrin in the ulcer-bearing skin of the leg: the cause of lipodermatosclerosis and venous ulceration. Br Med J (Clin Res Ed)1982;285(6348):1071-1072.
5.
5. Falanga V, Eaglstein WH. The “trap” hypothesis of venous ulceration. Lancet1993;341(8851):1006-1008.
6.
6. Partsch H. Compression therapy of the legs. Areview. J Dermatol Surg Oncol1991;17(10):799-805.
7.
7. Christopoulos D, Nicolaides AN, Szendro G. Venous reflux: quantification and correlation with the clinical severity of chronic venous disease. Br J Surg1988;75(4):352-356.
8.
8. Stemmer R, Marescaux J, Furderer C. [Compression therapy of the lower extremities particularly with compression stockings]. Hautarzt1980;31(7):355-365.
9.
9. Fletcher A, Cullum N, Sheldon TA. Asystematic review of compression treatment for venous leg ulcers. Br Med J1997;315(7108): 576-580.
10.
10. Margolis DJ, Berlin JA, Strom BL. Risk factors associated with the failure of a venous leg ulcer to heal. Arch Dermatol1999;135(8): 920-926.
11.
11. Burnand K, Thomas ML, O’Donnell T, et al. Relation between postphlebitic changes in the deep veins and results of surgical treatment of venous ulcers. Lancet1976;1(7966):936-938.
12.
12. Weitz JI, Byrne J, Clagett GP, et al. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation1996;94(11):3026-3049.
15. Partsch H. [Neuropathies of the ulcero-mutilating type. Clinical aspects, classification, circulation measurements]. Vasa Suppl1977; 6:1-48.
16.
16. Brand PW. Pathomechanics of diabetic (neuropathic) ulcer and its conservative management. In: Bergan JJ, Yao, JST, editors. Gangrene and severe ischaemia of the lower extremities. New York: Grune & Stratton; 1978. p. 185-189.
17.
17. Laing P. The development and complications of diabetic foot ulcers. Am J Surg1998;176(2A Suppl):11S-19S.
18.
18. Cruse PJ, Foord R. Afive-year prospective study of 23,649 surgical wounds. Arch Surg1973;107(2):206-210.
19.
19. Stadelmann WK, Digenis AG, Tobin GR. Impediments to wound healing. Am J Surg1998;176(2A Suppl):39S-47S.
20.
20. Pecoraro RE, Chen MS. Ascorbic acid metabolism in diabetes mellitus. Ann N Y Acad Sci1987;498:248-258.
21.
21. Loots MA, Lamme EN, Zeegelaar J, et al. Differences in cellular infiltrate and extracellular matrix of chronic diabetic and venous ulcers versus acute wounds. J Invest Dermatol1998;111(5):850-857.
22.
22. Mulder G, Jones R, Cederholm-Williams S, et al. Fibrin cuff lysis in chronic venous ulcers treated with a hydrocolloid dressing. Int J Dermatol1993;32(4):304-306.
23.
23. Steed DL, Donohoe D, Webster MW, et al. Effect of extensive debridement and treatment on the healing of diabetic foot ulcers. Diabetic Ulcer Study Group. J Am Coll Surg1996;183(1):61-64.
24.
24. Argenta LC, Morykwas MJ. Vacuum-assisted closure: a new method for wound control and treatment: clinical experience. Ann Plast Surg1997;38(6):563-576; discussion 577.
26. Eriksson E, Perez N, Slama J, et al. Treatment of chronic, nonhealing abdominal wound in a liquid environment. Ann Plast Surg1996;36(1):80-83.
27.
27. Kirsner RS, Mata SM, Falanga V, et al. Split-thickness skin grafting of leg ulcers. The University of Miami Department of Dermatology’s experience (1990-1993). Dermatol Surg1995;21(8):701-703.
28.
28. Harrison PV. Split-skin grafting of varicose leg ulcers—a survey and the importance of assessment of risk factors in predicting outcome from the procedure. Clin Exp Dermatol1988;13(1):4-6.
29.
29. Harvima IT, Virnes S, Kauppinen L, et al. Cultured allogeneic skin cells are effective in the treatment of chronic diabetic leg and foot ulcers. Acta Derm Venereol1999;79(3):217-220.
30.
30. Marcusson JA, Lindgren C, Berghard A, et al. Allogeneic cultured keratinocytes in the treatment of leg ulcers. A pilot study. Acta Derm Venereol1992;72(1):61-64.
31.
31. De Luca M, Albanese E, Cancedda R, et al. Treatment of leg ulcers with cryopreserved allogeneic cultured epithelium. A multicenter study. Arch Dermatol1992;128(5):633-638.
32.
32. Teepe RG, Koebrugge EJ, Ponec M, et al. Fresh versus cryopreserved cultured allografts for the treatment of chronic skin ulcers. Br J Dermatol1990;122(1):81-89.
33.
33. Lundeberg TC, Eriksson SV, Malm M. Electrical nerve stimulation improves healing of diabetic ulcers. Ann Plast Surg1992; 29(4):328-331.
34.
34. Baker LL, Chambers R, De Muth SK, et al. Effects of electrical stimulation onwoundhealing in patients with diabetic ulcers. Diabetes Care1997;20(3):405-412.
35.
35. Horwitz LR, Burke TJ, Carnegie D. Augmentation ofwoundhealing usingmonochromatic infrared energy. Exploration of a new technology forwoundmanagement. Adv Wound Care1999;12(1):35-40.
36.
36. Boykin JV Jr. The nitric oxide connection: hyperbaric oxygen therapy, becaplermin, and diabetic ulcer management. Adv Skin Wound Care2000;13(4 Pt 1):169-174.
37.
37. Cohen S, Carpenter G, Lembach KJ. Interaction of epidermal growth factor (EGF) with cultured fibroblasts. Adv Metab Disord1975;8:265-284.
38.
38. Robson MC, Phillips LG, Thomason A, et al. Platelet-derived growth factor BB for the treatment of chronic pressure ulcers. Lancet1992;339(8784):23-25.
39.
39. Yager DR, Zhang LY, Liang HX, et al. Wound fluids from human pressure ulcers contain elevated matrix metalloproteinase levels and activity compared to surgical wound fluids. J Invest Dermatol1996; 107(5):743-748.
40.
40. Hariawala MD, Horowitz JR, Esakof D, et al. VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts. J Surg Res1996;63(1):77-82.
41.
41. Andree C, Swain WF, Page CP, et al. In vivo transfer and expression of a human epidermal growth factor gene accelerates wound repair. Proc Natl Acad Sci U S A1994;91(25):12188-12192.
42.
42. Benn SI, Whitsitt JS, Broadley KN, et al. Particle-mediated gene transfer with transforming growth factor-beta1 c DNAs enhances wound repair in rat skin. J Clin Invest1996;98(12):2894-2902.
43.
43. Eming SA, Whitsitt JS, He L, et al. Particle-mediated gene transfer of PDGF isoforms promotes wound repair. J Invest Dermatol1999;112(3):297-302.
44.
44. Eriksson E, Yao F, Svensjo T, et al. In vivo gene transfer to skin and wound by microseeding. J Surg Res1998;78(2):85-91.
45.
45. Vogt PM, Thompson S, Andree C, et al. Genetically modified keratinocytes transplanted to wounds reconstitute the epidermis. Proc Natl Acad Sci U S A1994;91(20):9307-9311.
46.
46. Krueger GG, Jorgensen CM, Matsunami N, et al. Persistent transgene expression and normal differentiation of immortalized human keratinocytes in vivo. J Invest Dermatol1999;112(2):233-239.
47.
47. Hickman MA, Malone RW, Lehmann-Bruinsma K, et al. Gene expression following direct injection of DNAinto liver. Hum Gene Ther1994;5(12):1477-1483.
48.
48. Hengge UR, Chan EF, Foster RA, et al. Cytokine gene expression in epidermis with biological effects following injection of naked DNA. Nat Genet1995;10(2):161-166.
49.
49. Hengge UR, Walker PS, Vogel JC. Expression of naked DNA in human, pig, and mouse skin. J Clin Invest1996;97(12):2911-2916.
50.
50. Wolff JA, Malone RW, Williams P, et al. Direct gene transfer into mouse muscle in vivo. Science1990;247(4949 Pt 1):1465-1468.
51.
51. Baumgartner I, Pieczek A, Manor O, et al. Constitutive expression of ph VEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation1998;97(12):1114-1123.
52.
52. Losordo DW, Vale PR, Symes JF, et al. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of ph VEGF165 as sole therapy formyocardial ischemia. Circulation1998;98(25):2800-2804.
53.
53. Takeshita S, Tsurumi Y, Couffinahl T, et al. Gene transfer of naked DNA encoding for three isoforms of vascular endothelial growth factor stimulates collateral development in vivo. Lab Invest1996; 75(4):487-501.
54.
54. Zhang L, Li L, Hoffmann GA, et al. Depth-targeted efficient gene delivery and expression in the skin by pulsed electric fields: an approach to gene therapy of skin aging and other diseases. Biochem Biophys Res Commun1996;220(3):633-636.
55.
55. Titomirov AV, Sukharev S, Kistanova E. In vivo electroporation and stable transformation of skin cells of newborn mice by plasmid DNA. Biochim Biophys Acta1991;1088(1):131-134.
56.
56. Liu Y, Liggitt D, Zhong W, et al. Cationic liposome-mediated intravenous gene delivery. J Biol Chem1995;270(42):24864-24870.
57.
57. Zhu N, Liggitt D, Liu Y, et al. Systemic gene expression after intravenous DNA delivery into adult mice. Science1993;261(5118): 209-211.
58.
58. Saeki Y, Matsumoto N, Nakano Y, et al. Development and characterization of cationic liposomes conjugated with HVJ (Sendai virus): reciprocal effect of cationic lipid for in vitro and in vivo gene transfer. Hum Gene Ther1997;8(17):2133-2141.
59.
59. Jeschke MG, Richter G, Herndon DN, et al. Therapeutic success and efficacy of nonviral liposomal c DNA gene transfer to the skin in vivo is dose dependent. Gene Ther2001;8(23):1777-1784.
60.
60. Anderson WF. Human gene therapy. Nature1998;392(6679 Suppl):25-30.
61.
61. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science2003;302(5644):415-419.
62.
62. Lehrman S. Virus treatment questioned after gene therapy death. Nature1999;401(6753):517-518.
63.
63. Molnar-Kimber KL, Sterman DH, Chang M, et al. Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. Hum Gene Ther1998;9(14):2121-2133.
64.
64. Yang Y, Nunes FA, Berencsi K, et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A1994;91(10):4407-4411.
65.
65. Mitani K, Graham FL, Caskey CT, et al. Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector. Proc Natl Acad Sci U S A1995;92(9):3854-3858.
66.
66. Parks RJ, Chen L, Anton M, et al. Ahelper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci U S A1996;93(24): 13565-13570.
67.
67. Morsy MA, Caskey CT. Expanded-capacity adenoviral vectors— the helper-dependent vectors. Mol Med Today1999;5(1):18-24.
68.
68. Haecker SE, Stedman HH, Balice-Gordon RJ, et al. In vivo expression of full-length human dystrophin from adenoviral vectors deleted of all viral genes. Hum Gene Ther1996;7(15):1907-1914.
69.
69. Fisher KJ, Choi H, Burda J, et al. Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology1996;217(1):11-22.
70.
70. Kochanek S, Clemens PR, Mitani K, et al. Anew adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and betagalactosidase. Proc Natl Acad Sci U S A1996;93(12):5731-5736.
71.
71. Liechty KW, Nesbit M, Herlyn M, et al. Adenoviral-mediated overexpression of platelet-derived growth factor-B corrects ischemic impaired wound healing. J Invest Dermatol1999;113(3):375-383.
72.
72. Liechty KW, Sablich TJ, Adzick NS, et al. Recombinant adenoviralmediated gene transfer in ischemic impaired wound healing. Wound Repair Regen1999;7(3):148-153.
73.
73. Kotin RM, Linden RM, Berns KI. Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination. Embo J1992;11(13): 5071-5078.
74.
74. Su H, Lu R, Kan YW. Adeno-associated viral vector-mediated vascular endothelial growth factor gene transfer induces neovascular formation in ischemic heart. Proc Natl Acad Sci U S A2000;97(25): 13801-13806.
75.
75. Marconi P, Krisky D, Oligino T, et al. Replication-defective herpes simplex virus vectors for gene transfer in vivo. Proc Natl Acad Sci U S A1996;93(21):11319-11320.
76.
76. Fink DJ, De Luca NA, Yamada M, et al. Design and application of HSV vectors for neuroprotection. Gene Ther2000;7(2):115-119.
77.
77. Yao F, Eriksson E. A novel anti-herpes simplex virus type 1-specific herpes simplex virus type 1 recombinant. Hum Gene Ther1999;10(11):1811-1818.
78.
78. Berthomme H, Lokensgard J, Yang L, et al. Evidence for a bidirectional element located downstream from the herpes simplex virus type 1 latency-associated promoter that increases its activity during latency. J Virol2000;74(8):3613-3622.
79.
79. Wolfe D, Goins WF, Kaplan TJ, et al. Herpesvirus-mediated systemic delivery of nerve growth factor. Mol Ther2001;3(1):61-69.
80.
80. Goss JR, Goins WF, Lacomis D, et al. Herpes simplex-mediated gene transfer of nerve growth factor protects against peripheral neuropathy in streptozotocin-induced diabetes in the mouse. Diabetes2002;51(7):2227-2232.
81.
81. Beck LS, De Guzman L, Lee WP, et al. One systemic administration of transforming growth factor-beta 1 reverses age- or glucocorticoid-impaired wound healing. J Clin Invest1993;92(6):2841-2849.
82.
82. Breuing K, Andree C, Helo G, et al. Growth factors in the repair of partial thickness porcine skin wounds. Plast Reconstr Surg1997; 100(3):657-664.
83.
83. Brown RL, Breeden MP, Greenhalgh DG. PDGF and TGF-alpha act synergistically to improve wound healing in the genetically diabetic mouse. J Surg Res1994;56(6):562-570.
84.
84. Buckley A, Davidson JM, Kamerath CD, et al. Sustained release of epidermal growth factor accelerates wound repair. Proc Natl Acad Sci U S A1985;82(21):7340-7344.
86. Eming SA, Medalie DA, Tompkins RG, et al. Genetically modified human keratinocytes overexpressing PDGF-A enhance the performance of a composite skin graft. Hum Gene Ther1998;9(4):529-539.
87.
87. Falanga V, Eaglstein WH, Bucalo B, et al. Topical use of human recombinant epidermal growth factor (h-EGF) in venous ulcers. J Dermatol Surg Oncol1992;18(7):604-606.
88.
88. Greenhalgh DG, Sprugel KH, Murray MJ, et al. PDGF and FGF stimulate wound healing in the genetically diabetic mouse. Am J Pathol1990;136(6):1235-1246.
89.
89. Hebda PA, Klingbeil CK, Abraham JA, et al. Basic fibroblast growth factor stimulation of epidermal wound healing in pigs. J Invest Dermatol1990;95(6):626-631.
90.
90. Lynch SE, Nixon JC, Colvin RB, et al. Role of platelet-derived growth factor in wound healing: synergistic effects with other growth factors. Proc Natl Acad Sci U S A1987;84(21):7696-7700.
91.
91. Lynch SE, Williams RC, Polson AM, et al. A combination of platelet-derived and insulin-like growth factors enhances periodontal regeneration. J Clin Periodontol1989;16(8):545-548.
92.
92. Mellin TN, Mennie RJ, Cashen DE, et al. Acidic fibroblast growth factor accelerates dermal wound healing. Growth Factors1992; 7(1):1-14.
93.
93. Boyce N. Trial halted after gene shows up in semen. Nature2001;414(6865):677-677.
94.
94. Svensjo T, Yao F, Pomahac B, et al. Autologous keratinocyte suspensions accelerate epidermal wound healing in pigs. J Surg Res2001;99(2):211-221.
95.
95. Manuscript submitted for publication.
96.
96. Grosskreutz CL, Anand-Apte B, Duplaa C, et al. Vascular endothelial growth factor-induced migration of vascular smooth muscle cells in vitro. Microvasc Res1999;58(2):128-136.
97.
97. Wright CE. Effects of vascular endothelial growth factor (VEGF)A and VEGFB gene transfer on vascular reserve in a conscious rabbit hindlimb ischaemia model. Clin Exp Pharmacol Physiol2002; 29(11):1035-1039.
98.
98. Rivard A, Silver M, Chen D, et al. Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapywith adeno-VEGF. Am J Pathol1999;154(2):355-363.
99.
99. Gowdak LH, Poliakova L, Wang X, et al. Adenovirus-mediated VEGF(121) gene transfer stimulates angiogenesis in normoperfused skeletal muscle and preserves tissue perfusion after induction of ischemia. Circulation2000;102(5):565-571.
100.
100. Gowdak LH, Poliakova L, Li Z, et al. Induction of angiogenesis by cationic lipid-mediated VEGF165 gene transfer in the rabbit ischemic hindlimb model. J Vasc Surg2000;32(2):343-352.
101.
101. Mesri EA, Federoff HJ, Brownlee M. Expression of vascular endothelial growth factor from a defective herpes simplex virus type 1 amplicon vector induces angiogenesis in mice. Circ Res1995;76(2): 161-167.
102.
102. Ohara N, Koyama H, Miyata T, et al. Adenovirus-mediated ex vivo gene transfer of basic fibroblast growth factor promotes collateral development in a rabbitmodel of hind limb ischemia. Gene Ther2001;8(11):837-845.
103.
103. Makinen K, Manninen H, Hedman M, et al. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebocontrolled, double-blinded phase II study. Mol Ther2002;6(1): 127-133.
104.
104. Laitinen M, Makinen K, Manninen H, et al. Adenovirusmediated gene transfer to lower limb artery of patients with chronic critical leg ischemia. Hum Gene Ther1998;9(10):1481-1486.
105.
105. Isner JM, Baumgartner I, Rauh G, et al. Treatment of thromboangiitis obliterans (Buerger’s disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results. J Vasc Surg1998;28(6):964-973; discussion 73-5.
106.
106. Shyu KG, Chang H, Wang BW, et al. Intramuscular vascular endothelial growth factor gene therapy in patients with chronic critical leg ischemia. Am J Med2003;114(2):85-92.
107.
107. Kalka C, Masuda H, Takahashi T, et al. Vascular endothelial growth factor(165) gene transfer augments circulating endothelial progenitor cells in human subjects. Circ Res2000;86(12):1198-1202.
108.
108. Breitbart AS, Laser J, Parrett B, et al. Accelerated diabetic wound healing using cultured dermal fibroblasts retrovirally transduced with the platelet-derived growth factor B gene. Ann Plast Surg2003;51(4):409-414.
109.
109. Supp DM, Bell SM, Morgan JR, et al. Genetic modification of cultured skin substitutes by transduction of human keratinocytes and fibroblasts with platelet-derived growth factor-A. Wound Repair Regen2000;8(1):26-35.
110.
110. Lee RJ, Springer ML, Blanco-Bose WE, et al. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation2000;102(8):898-901.
111.
111. Rivard A, Fabre JE, Silver M, et al. Age-dependent impairment of angiogenesis. Circulation1999;99(1):111-120.
112.
112. Murohara T, Asahara T, Silver M, et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest1998;101(11):2567-2578.
113.
113. Van Belle E, Rivard A, Chen D, et al. Hypercholesterolemia attenuates angiogenesis but does not preclude augmentation by angiogenic cytokines. Circulation1997;96(8):2667-2674.
114.
114. Schratzberger P, Schratzberger G, Silver M, et al. Favorable effect of VEGF gene transfer on ischemic peripheral neuropathy. Nat Med2000;6(4):405-413.
115.
115. Galeano M, Deodato B, Altavilla D, et al. Adeno-associated viral vector-mediated human vascular endothelial growth factor gene transfer stimulates angiogenesis and wound healing in the genetically diabetic mouse. Diabetologia2003;46(4):546-555.
116.
116. Chesnoy S, Lee PY, Huang L. Intradermal injection of transforming growth factor-beta1 gene enhances wound healing in genetically diabetic mice. Pharm Res2003;20(3):345-350.
117.
117. Hansen SL, Myers CA, Charboneau A, et al. Hox D3 accelerates wound healing in diabetic mice. Am J Pathol2003;163(6):2421-2431.
118.
118. Rebar EJ, Huang Y, Hickey R, et al. Induction of angiogenesis in a mouse model using engineered transcription factors. Nat Med2002; 8(12):1427-1432.
119.
119. Vincent KA, Shyu KG, Luo Y, et al. Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1alpha/VP16 hybrid transcription factor. Circulation2000;102(18): 2255-2261.
120.
120. Yao F, Svensjo T, Winkler T, et al. Tetracycline repressor, tet R, rather than the tet R-mammalian cell transcription factor fusion derivatives, regulates inducible gene expression in mammalian cells. Hum Gene Ther1998;9(13):1939-1950.
121.
121. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci U S A1992;89(12):5547-5551.
